Europlasma SA announced consolidated earnings results for the half year ended June 30, 2016. For the period, the company reported revenue of €5.709 million compared to €6.903 million a year ago. LBITDA was €4.979 million compared to €4.887 million a year ago. Operating loss was €8.571 million compared to €8.835 million a year ago. Net loss was €9.024 million or €0.13 per share compared to €9.768 million or €0.14 per share a year ago. The decline in revenue is mainly attributable to the Asbestos Treatment (- €863,000) and Renewable Energies activities (-€557,000), with growth in the Plasma Solutions division (€226,000) not managing to offset the under-performance of these other two branches. Net debt was €10.750 million compared to €5.709 million a year ago. Cash flow used in operations was €5.980 million compared to €4.903 million a year ago.